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 This is the first study to show a correlation between DNA methylation and expression of miR-200c and miR-141 in clinical prostate specimens. 
 Our findings provide evidence that expression of miR-200c and miR-141 is regulated by methylation of CpG sites in their promoter in PCa cells. 
 Profiling their expression and methylation status may therefore have potential as a novel biomarker in the diagnosis and prognosis of PCa. 
 Our data also suggests that aberrant miR-200c/miR-141 expression will affect DNMT3A and TET genes, key components of the methylation machinery which will influence global cellular 
methylation levels. 
 Furthermore, we propose that manipulation of miR-200c and miR-141 expression by epigenetic alterations, either through chemical or dietary means, may be the basis for a possible 
therapeutic intervention for this disease.
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In prostate cancer, many miRNAs are aberrantly expressed.
This abnormal expression suggests that miRNAs are potentially
promising in terms of diagnosis, prognosis and subsequent
therapeutic intervention in this disease1, 2.
miR-200c and miR-141 are co-expressed members of the miR-
200 family, which play a key role in epithelial-to-mesenchymal
transition (EMT) in cancer.
miR-200c and miR-141 are known to be abnormally expressed
in several cancers, including prostate cancer 3, 4.
Epigenetic regulation of miR-200c via DNA methylation has
also been reported in various cancers 5-7, but no studies to date
have investigated this in prostate cancer.
We therefore proceeded to profile and correlate miR-200c/miR-
141 expression and methylation status in prostate cell-lines and
clinical prostate samples.
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Cell Lines: Non-malignant prostate epithelial cell-line RWPE1 and
human prostate cancer cell-lines PC3, 22RV1 and LNCaP.
Transfections performed at final concentration of 25nM.
Clinical Prostate Samples: Five 10M sections were prepared
from FFPE needle core biopsies (n=14) and FFPE prostatectomy
biopsy samples (n=22) for RNA and DNA extraction using
RecoverAll™ Total Nucleic Acid Isolation Kit for FFPE (Life
Technologies). ORECNNI Ref: 10/NIR02/13.
PCR: miRCURY LNATM microRNA PCR system (Exiqon, Denmark)
used to measure miR-200c and miR-141 expression from 50ng
(clinical samples) or 20ng (cell-line samples) template RNA. miRNA
and gene expression performed on Roche LC480 Lightcycler.
Flow Cytometry: performed on Beckman-Coulter Gallios™
instrument using PI staining (cell cycle) or PI and Alexa® Flour 488-
Annexin V Kit (apoptosis) (Life Technologies).
Aza and Genistein Treatment: PC3 cells were treated with
decitabine (5-aza-2'-deoxycytidine) (1µM) for 72hours or genistein
(40µM) for 120 hours. RNA and DNA extracted for analysis.
Pyrosequencing/COBRA: Bisulfite converted DNA was produced
using the EpiTect Bisulfite Kit (Qiagen). The PyroMarkTM Q24
pyrosequencer (Qiagen) was used to measure methylation levels
within the miR-200c/miR-141 promoter region across CpG sites.
Restriction enzymes BstU1 and Hinf1 was used in COBRA analysis.
Other Assays: XTT proliferation assay (Roche) and colony assay
performed on transfected and control cells.
(A) qRT-PCR analysis of miR-200c and miR-141 expression in LNCaP, 22RV1, DU145 and PC3 prostate cancer
cell lines and normal prostate epithelial cell line RWPE1. (B) and (C) qRT-PCR analysis of RNA isolated from
needle core biopsy clinical specimens (n = 14) and prostatectomy biopsy clinical specimens (n = 22) showing fold
change expression of miR-200c and miR-141 in individual tumour cases relative to matched normal tissue. (D)
Demethylation treatment by knockdown of DNA Methyltransferase 1 (siDNMT1) in PC3 cells resulted in significantly
increased expression of miR-200c and miR-141 (Student t-test p-values: *p<0.05, **p<0.01, ***p<0.001).
FIGURE 1. Expression of miR-200c and miR-141 in PCa cells and tissues
(A) Assay design for COBRA and pyrosequencing. (B) COBRA methylation analysis at the BstU1 site & (C)
Hinf1 site demonstrates no methylation in LNCaP, 22RV1 or DU145 cells at either site. Hypermethylation at
both sites in PC3 cells is indicated by digest products of 171bp and 95bp respectively. (D) Pyrosequencing of
miR-200c/miR-141 promoter Region 1 (Prom 1) and (E) Region 2 & 3 combined (Prom 2 & 3) displays low
methylation in LNCaP, 22RV1 cells and DU145, but significant hypermethylation in PC3 cells relative to normal
RWPE1 cells. Control cells (HCT116; colon cancer cell line, DKO; fibroblasts with DNMT1 and DNMT3B
knockout, PBL; peripheral blood lymphocytes). (Student t-test p-values: *p<0.05, **p<0.01, ***p<0.001).
FIGURE 2. Methylation analysis of miR-200c/miR-141 promoter in PCa cell lines
FIGURE 3. Methylation analysis of miR-200c/miR-141 promoter in prostate cancer 
tissues
FIGURE 4. Expression of miR-200c and miR-141 correlates with promoter 
methylation in prostate cancer tissue
(A) Pyrosequencing analysis of DNA isolated from prostatectomy biopsy clinical specimens showing average
methylation at 16 separate CpG sites within the miR-200c/miR-141 promoter in paired tumour samples relative to
matched normal tissue (n = 14). Data represents mean ± SE of triplicate experiments. Below, the average methylation
in all 14 paired tumour and normal samples is presented separately for (B) Prom 1, (C) Prom 2 and (D) Prom 3
regions of miR-200c/miR-141 promoter. Each dot represents the mean methylation percentage of all the
pyrosequenced CpG sites in that region.
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Mean expression of (A) miR-200c and (B) miR-141 shows a significant inverse correlation with the mean
methylation percentage of the Prom 3 region of the miR-200c/miR-141 promoter. Cases with <40% methylation
in the Prom 3 region showed significantly higher expression of (C) miR-200c and (D) miR-141 than those with
methylation >60% in this region. (E) Treatment with decitabine (AZA) resulted in significant demethylation of
CpG sites in the Prom 3 region and (F) up-regulation of miR-200c and miR-141. (Student t-test p-values:
*p<0.05, **p<0.01, ***p<0.001).
REFERENCES
1. Wen et al, Am J Clin Exp Urol. 2014 2(3):219-30
2. Jackson et al, BMC Cancer. 2014 19:930
3. Massoner et al, Br J Cancer. 2014 111(5):955-64
4. Puhr et al, Am J Pathol. 2012 181(6):2188-201
5. Wiklund et al, Int J Cancer. 2011 128, 1327-1334
6. Tamagawa et al, Int J Mol Med. 2014 33(4):879-86
7. Zhou et al, Med Oncol. 2015 32(1):428
FIGURE 5. miR-200c over-expression inhibits cell growth and induces apoptosis FIGURE 6. miR-200c and miR-141 target genes involved in cell methylation
(A) and (B) XTT Proliferation assay showing that miR-200c over-expression decreases viability of PC3 cells. (C)
Representative images and quantification of crystal violet staining demonstrates that miR-200c over-expression
significantly inhibits the colony formation ability of PC3 cells. (D) and (E) Quantification of Annexin V apoptosis
assay showing that miR-200c over-expression induces apoptosis in PC3 cells. (F) Western blot demonstrating
increase of PARP cleavage in miR-200c transfectants compared to control cells. (Student t-test p-values: *p<0.05,
**p<0.01, ***p<0.001).
(A) miR-200c is computationally predicted to target DNMT3A. (B) PCR shows that over-expression of miR-
200c in PC3 cells results in significant down-regulation of DNMT3A, SOX2 and ZEB1. (C) miR-141 is
computationally predicted to target TET1 and TET3. (D) PCR shows that over-expression of miR-141 in PC3
cells results in significant down-regulation of TET1, TET3 and ZEB1. (D) Pyrosequencing analysis shows
treatment of PC3 cells with genistein (40M daily for 7 days) results in significant demethylation of miR-
200c/miR-141 promoter region 3 (Prom 3). (F) In the same genistein-treated PC3 cells, miR-200c expression is
significantly increased as measured by PCR. (Student t-test p-values: *p<0.05, **p<0.01, ***p<0.001).
